株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

化学療法誘発性末梢神経障害:パイプライン製品の分析

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 245976
出版日 ページ情報 英文 136 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.47円で換算しております。
Back to Top
化学療法誘発性末梢神経障害:パイプライン製品の分析 Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2017
出版日: 2017年03月31日 ページ情報: 英文 136 Pages
概要

化学療法誘発性末梢神経障害 (CIPN) は、がん治療の副作用の一種です。主な症状として、疼痛や灼熱感、刺すような痛み、便秘、筋力低下、血圧の変動、バランス感覚の喪失などが挙げられます。主なリスク要因には、治療の長期化や、以前から罹患している神経症、化学療法用の医薬品の種類などがあります。

当レポートでは、世界各国での化学療法誘発性末梢神経障害治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

化学療法誘発性末梢神経障害;概要

化学療法誘発性末梢神経障害 - 治療薬の開発

  • パイプラインの概要
  • 各企業で開発中の治療薬
  • 大学/研究機関別のパイプライン製品
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Achelios Therapeutics Inc
  • Advinus Therapeutics Ltd
  • Apollo Endosurgery Inc
  • Aptinyx Inc
  • Asahi Kasei Pharma Corp
  • Can-Fite BioPharma Ltd
  • Celgene Corp
  • DermaXon LLC
  • エーザイ
  • Immune Pharmaceuticals Inc
  • INSYS Therapeutics Inc
  • Kineta Inc
  • KPI Therapeutics Inc
  • Krenitsky Pharmaceuticals Inc
  • MAKScientific LLC
  • Metys Pharmaceuticals AG
  • Midatech Pharma US Inc
  • Mundipharma International Ltd
  • Nemus Bioscience Inc
  • Neurocentrx Pharma Ltd
  • Panacea Pharmaceuticals Inc
  • PeriphaGen Inc
  • PharmatrophiX Inc
  • PledPharma AB
  • Sova Pharmaceuticals Inc
  • Virobay Inc
  • WEX Pharmaceuticals Inc

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9113IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 1, 23, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chemotherapy Induced Peripheral Neuropathy - Overview
    • Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development
    • Achelios Therapeutics Inc
    • Advinus Therapeutics Ltd
    • Apollo Endosurgery Inc
    • Aptinyx Inc
    • Asahi Kasei Pharma Corp
    • Can-Fite BioPharma Ltd
    • Celgene Corp
    • DermaXon LLC
    • Eisai Co Ltd
    • Immune Pharmaceuticals Inc
    • INSYS Therapeutics Inc
    • Kineta Inc
    • KPI Therapeutics Inc
    • Krenitsky Pharmaceuticals Inc
    • MAKScientific LLC
    • Metys Pharmaceuticals AG
    • Midatech Pharma US Inc
    • Mundipharma International Ltd
    • Nemus Bioscience Inc
    • Neurocentrx Pharma Ltd
    • Panacea Pharmaceuticals Inc
    • PeriphaGen Inc
    • PharmatrophiX Inc
    • PledPharma AB
    • Sova Pharmaceuticals Inc
    • Virobay Inc
    • WEX Pharmaceuticals Inc
  • Chemotherapy Induced Peripheral Neuropathy - Drug Profiles
    • (amitriptyline + ketamine hydrochloride) - Drug Profile
    • ACY-1083 - Drug Profile
    • AM-1710 - Drug Profile
    • APX-2009 - Drug Profile
    • APX-3330 - Drug Profile
    • BR-297 - Drug Profile
    • cannabidiol - Drug Profile
    • dimiracetam - Drug Profile
    • Drugs for Peripheral Neuropathy - Drug Profile
    • DX-0332 - Drug Profile
    • E-2072 - Drug Profile
    • HM-01 - Drug Profile
    • KCP-400 - Drug Profile
    • ketoprofen - Drug Profile
    • KP-544 - Drug Profile
    • KRN-5500 - Drug Profile
    • LM-11A31BHS - Drug Profile
    • Lpathomab - Drug Profile
    • MR-309 - Drug Profile
    • NB-2111 - Drug Profile
    • NRX-2922 - Drug Profile
    • NT-24336 - Drug Profile
    • PAN-811 - Drug Profile
    • PGN-503 - Drug Profile
    • piclidenoson - Drug Profile
    • pirenzepine hydrochloride - Drug Profile
    • PP-095 - Drug Profile
    • Q-201 - Drug Profile
    • ricolinostat - Drug Profile
    • Small Molecule to Inhibit Cystathionine Gamma Lyase for Inflammatory Pain and Chemotherapy Induced Peripheral Neuropathy - Drug Profile
    • Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
    • Small Molecules for Pain - Drug Profile
    • Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
    • Small Molecules to Block Nav 1.8 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
    • Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile
    • Tetrodotoxin - Drug Profile
    • thrombomodulin alfa - Drug Profile
    • U-2902 - Drug Profile
    • VBY-036 - Drug Profile
    • XEN-106 - Drug Profile
    • XT-150 - Drug Profile
  • Chemotherapy Induced Peripheral Neuropathy - Dormant Projects
  • Chemotherapy Induced Peripheral Neuropathy - Discontinued Products
  • Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Advinus Therapeutics Ltd, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Apollo Endosurgery Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Pharma Corp, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Can-Fite BioPharma Ltd, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Celgene Corp, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by DermaXon LLC, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co Ltd, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by INSYS Therapeutics Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by KPI Therapeutics Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific LLC, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Metys Pharmaceuticals AG, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Midatech Pharma US Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mundipharma International Ltd, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Neurocentrx Pharma Ltd, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Virobay Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2017
  • Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top